AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,360.50GBp
12:08pm EDT
Price Change (% chg)

-81.00p (-1.82%)
Prev Close
4,441.50p
Open
4,420.00p
Day's High
4,437.50p
Day's Low
4,359.50p
Volume
2,064,723
Avg. Vol
2,220,894
52-wk High
4,946.41p
52-wk Low
3,106.00p

AZN.L

Chart for AZN.L

About

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes treatments... (more)

Overall

Beta: 0.39
Market Cap (Mil.): £56,181.34
Shares Outstanding (Mil.): 1,262.72
Dividend: 53.10
Yield (%): 3.83

Financials

  AZN.L Industry Sector
P/E (TTM): 44.94 33.37 34.07
EPS (TTM): 0.99 -- --
ROI: 5.03 18.15 17.40
ROE: 8.94 18.85 18.25
Search Stocks

UPDATE 2-Ardelyx, AstraZeneca bowel drug succeeds in mid-stage trial

Oct 1 - Ardelyx Inc said its experimental drug to treat constipation-related irritable bowel syndrome achieved the main goal of increasing bowel movement compared with a placebo in a mid-stage study involving 371 patients.

10:39am EDT

No benefit from continued use of AstraZeneca's Iressa drug

MADRID - Continuing to give AstraZeneca's drug Iressa plus chemotherapy to lung cancer patents whose disease has worsened after previously taking the medicine on its own does not provide any benefit.

28 Sep 2014

No benefit from continued use of AstraZeneca's Iressa drug

MADRID, Sept 28 - Continuing to give AstraZeneca's drug Iressa plus chemotherapy to lung cancer patents whose disease has worsened after previously taking the medicine on its own does not provide any benefit.

28 Sep 2014

Early data promising for AstraZeneca cancer drug combination

MADRID - Early results for a closely watched cancer drug combination from AstraZeneca that boosts the immune system show the cocktail is promising, though limited patient numbers mean the data is far from conclusive.

27 Sep 2014

AstraZeneca sticks to H2 2015 timetable for new lung cancer pill

MADRID, Sept 27 - AstraZeneca said on Saturday it expected to file a new lung cancer pill for U.S. regulatory approval in the second half of 2015, potentially disappointing some investors who had hoped the drug might be ready faster.

27 Sep 2014

UPDATE 1-Early data promising for AstraZeneca cancer drug combination

* MEDI4736, tremelimumab combination tested in lung cancer

27 Sep 2014

Early data promising for AstraZeneca cancer drug combination

* MEDI4736, tremelimumab combination tested in lung cancer

27 Sep 2014

AstraZeneca says expanded use of lung cancer drug backed by EU agency

LONDON - European regulators have recommended wider use of AstraZeneca's IRESSA treatment for lung cancer, the British pharmaceutical company said on Friday.

26 Sep 2014

EU agency backs AstraZeneca's MOVENTIG drug

LONDON - A drug for the treatment of opioid-induced constipation, MOVENTIG, from AstraZeneca, was recommended for approval by European regulators on Friday.

26 Sep 2014

EU agency backs AstraZeneca's MOVENTIG drug

LONDON, Sept 26 - A drug for the treatment of opioid-induced constipation, MOVENTIG, from AstraZeneca, was recommended for approval by European regulators on Friday.

26 Sep 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks